SEC Form 4 · accession 0001468308-26-000028
FENNEC PHARMACEUTICALS INC. · FENC
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Robert Andrade
Officer — CHIEF FINANCIAL OFFICER
Period of report
Aug 27, 2026
Accepted (ET)
Aug 28, 2026 · 5:42 pm EDT
Rule 10b5-1 plan
yes — trade under a plan
Issuer CIK
0001211583
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common sharesF1 | Aug 27, 2026 | S | 75,000 | $11.78 | D | 217,675 | D | |
| Common sharesF2 | Aug 28, 2026 | M | 21,928 | $5.10 | A | 239,603 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock OptionsF2 | $5.10 | Aug 28, 2026 | M | 21,928 | D | Jun 27, 2017 | Jun 27, 2027 | Common Shares | 21,928 | 779,330 | D |
Explanation of responses
- F1Represents shares sold pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 22, 2026, which is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). A portion of the sales proceeds from this transaction will be used by the reporting person to pay tax obligations of the reporting person.
- F2Shares acquired through the exercise of an option contract with exercise price of $5.10 and an expiration date of June 27, 2027.